SI2167033T1 - Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan - Google Patents

Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan

Info

Publication number
SI2167033T1
SI2167033T1 SI200831836T SI200831836T SI2167033T1 SI 2167033 T1 SI2167033 T1 SI 2167033T1 SI 200831836 T SI200831836 T SI 200831836T SI 200831836 T SI200831836 T SI 200831836T SI 2167033 T1 SI2167033 T1 SI 2167033T1
Authority
SI
Slovenia
Prior art keywords
tacrolimus
dosage form
oral dosage
once daily
daily oral
Prior art date
Application number
SI200831836T
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Anne-Marie Lademann
Original Assignee
Veloxis Pharmaceuticals A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2167033(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veloxis Pharmaceuticals A/S filed Critical Veloxis Pharmaceuticals A/S
Publication of SI2167033T1 publication Critical patent/SI2167033T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200831836T 2007-05-30 2008-05-30 Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan SI2167033T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700783 2007-05-30
DKPA200701573 2007-11-07
EP08748829.2A EP2167033B1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus
PCT/DK2008/050130 WO2008145143A1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus

Publications (1)

Publication Number Publication Date
SI2167033T1 true SI2167033T1 (sl) 2017-08-31

Family

ID=39766919

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831836T SI2167033T1 (sl) 2007-05-30 2008-05-30 Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan

Country Status (10)

Country Link
US (7) US8685998B2 (sl)
EP (1) EP2167033B1 (sl)
CA (1) CA2688381C (sl)
DK (1) DK2167033T3 (sl)
ES (1) ES2634153T3 (sl)
HU (1) HUE033011T2 (sl)
LT (1) LT2167033T (sl)
PL (1) PL2167033T4 (sl)
SI (1) SI2167033T1 (sl)
WO (1) WO2008145143A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020994A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
WO2008015018A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CA2688381C (en) 2007-05-30 2016-10-11 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
US20220193046A1 (en) * 2007-05-30 2022-06-23 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
ES2591352T3 (es) * 2010-02-17 2016-11-28 Veloxis Pharmaceuticals A/S Composición de tacrolimus estabilizada
US20120203573A1 (en) 2010-09-22 2012-08-09 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
US20120072231A1 (en) * 2010-09-22 2012-03-22 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
EP2589383A1 (en) * 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
FR2986532B1 (fr) * 2012-02-07 2015-03-13 Polymerexpert Sa Compositions polymeres metastables pour dispositifs d'injection d'implants ophtalmiques
PL3030232T3 (pl) 2013-04-29 2022-11-07 Medregen, Llc Gojenie ran poprzez autologiczną mobilizację komórek macierzystych
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US20220296572A1 (en) 2021-03-03 2022-09-22 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114469847A (zh) * 2021-12-29 2022-05-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
ATE183083T1 (de) 1992-11-18 1999-08-15 Fujisawa Pharmaceutical Co Pharmazeutische zubereitung mit verlängerter wirkung
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001250646A1 (en) 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
WO2001095939A1 (en) 2000-06-12 2001-12-20 Smithkline Beecham Corporation Novel solid dispersion compositions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
JP4570357B2 (ja) 2001-07-06 2010-10-27 ライフサイクル ファーマ エー/エス 制御された凝集
EP1641437A4 (en) 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
PT1663217E (pt) * 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
WO2005020994A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
EA011244B1 (ru) 2004-03-18 2009-02-27 Панацея Биотек Лтд. Новые композиции для местной доставки
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1835889A1 (en) 2004-12-15 2007-09-26 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
KR100678824B1 (ko) 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
EP1868576A2 (en) 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CA2612829A1 (en) 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
KR100693461B1 (ko) 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
JP2008037808A (ja) 2006-08-07 2008-02-21 Astellas Pharma Inc タクロリムスカプセル剤
JPWO2008041553A1 (ja) * 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
JP2010522742A (ja) * 2007-03-29 2010-07-08 パナセア バイオテック リミテッド タクロリムスの修飾型剤形
CA2688381C (en) 2007-05-30 2016-10-11 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus

Also Published As

Publication number Publication date
US20210046054A1 (en) 2021-02-18
US20100105717A1 (en) 2010-04-29
CA2688381C (en) 2016-10-11
US20120029009A1 (en) 2012-02-02
EP2167033B1 (en) 2017-04-19
US8664239B2 (en) 2014-03-04
US10864199B2 (en) 2020-12-15
EP2167033A1 (en) 2010-03-31
US11123331B2 (en) 2021-09-21
US20160243091A1 (en) 2016-08-25
DK2167033T3 (en) 2017-08-14
US20110275659A1 (en) 2011-11-10
LT2167033T (lt) 2017-08-10
US8685998B2 (en) 2014-04-01
PL2167033T4 (pl) 2018-08-31
US11110081B2 (en) 2021-09-07
CA2688381A1 (en) 2008-12-04
PL2167033T3 (pl) 2017-12-29
ES2634153T3 (es) 2017-09-26
HUE033011T2 (hu) 2017-11-28
WO2008145143A1 (en) 2008-12-04
US20140179731A1 (en) 2014-06-26
US20210046055A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
SI2167033T1 (sl) Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
IL206159A0 (en) Oral pharmaceutical dosage forms
PL2077729T3 (pl) Doustne postacie dawkowania probiotyku
SI2399580T1 (sl) Farmacevtske odmerne oblike
IL205160A0 (en) Oral dosage forms comprising licarbazepine acetate
ZA201006029B (en) Pharmaceutical dosage form
PT2361081T (pt) Forma de dosagem intra-oral multiporção e seu uso
GB0710439D0 (en) Oral dosage form
HK1154484A1 (en) Oral dosage composition
ZA200903858B (en) Pharmaceutical dosage form
HK1137363A1 (en) Novel dosage form
HK1206267A1 (en) Stabilized picoplatin oral dosage form
GB0616794D0 (en) Solid dosage form
GB0822124D0 (en) Oral dosage form
PL2008940T3 (pl) Butelka dozująca
GB0615064D0 (en) Medicament
GB0717450D0 (en) Medicament
GB0615814D0 (en) Medicament
HK1115054A1 (en) Preparation for oral administration
GB0704123D0 (en) Dosage form